Is a minimum 24‑hour interval required between Spravato (esketamine) doses during the induction phase?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Spravato Dosing Interval During Induction Phase

No, a strict 24-hour minimum interval is not required between Spravato doses during the induction phase—the FDA-approved regimen is twice-weekly dosing, which typically allows 3-4 days between doses. 1

FDA-Approved Induction Dosing Schedule

The FDA label for Spravato clearly specifies twice-weekly administration during the 4-week induction phase 1. This translates to dosing on a schedule such as Monday/Thursday or Tuesday/Friday, providing approximately 72-96 hours between doses—substantially more than 24 hours.

Key Clinical Trial Evidence

The pivotal registration trials (Study 1 and Study 2) that established Spravato's efficacy used this twice-weekly induction protocol:

  • Study 1 enrolled 223 patients with treatment-resistant depression who received either intranasal esketamine (56 mg or 84 mg) or placebo, both groups receiving twice-weekly dosing for 4 weeks 1
  • Patients demonstrated significant improvement by 24 hours after the first dose, with continued benefit through day 28 1
  • At day 28,67% of patients were receiving the 84 mg dose twice weekly 1

Clinical Rationale for Twice-Weekly Spacing

The twice-weekly (not daily or every-other-day) schedule reflects several important considerations:

  • Pharmacodynamic effects: Esketamine's antidepressant effects persist beyond its brief pharmacokinetic half-life, with improvements observed at 24 hours and sustained for 3-7 days 2
  • Safety monitoring: The REMS program requires 2-hour post-dose observation for sedation, dissociation, and blood pressure changes 2—twice-weekly dosing makes this supervision logistically feasible
  • Adverse event management: Common acute side effects (dissociation, dizziness, nausea) occur on dosing days and typically resolve within 1.5 hours 3—allowing 3-4 days between doses provides recovery time

Common Pitfall to Avoid

Do not confuse the twice-weekly induction schedule with daily dosing. The evidence base and FDA approval specifically support twice-weekly administration. More frequent dosing (e.g., every 24 hours) has not been studied in the registration trials and would increase adverse event burden, particularly dissociative symptoms (RR 7.33 compared to placebo) 4 and blood pressure elevations (RR 3.96) 4.

Practical Implementation

During the 4-week induction phase:

  • Administer esketamine twice per week (e.g., every 3-4 days)
  • Start with 56 mg; may increase to 84 mg from the second dose onward based on efficacy and tolerability 1
  • Maintain concurrent oral antidepressant therapy throughout 1
  • Ensure 2-hour supervised observation after each dose 2

The guideline evidence supports this approach, noting that "twice-weekly dosing of esketamine as augmentation to ongoing oral antidepressant use improved depressive symptoms and remission rates" at 28 days 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.